CoChat

High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort

Open access
Taipale, Heidi, Koponen, Marjaana, Tanskanen, Antti, Tolppanen, Anna-Maija, Tiihonen, Jari, Hartikainen, Sirpa · 2014 · European Neuropsychopharmacology
Cited by 73

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Psychotropic drugs are used for treatment of behavioral and psychological symptoms of dementia (BPSD) although they are associated with serious adverse drug events. Objective of our study was to investigate prevalence of psychotropic drug use one year after diagnoses of Alzheimer's disease (AD), to compare prevalence to persons without AD and to assess changes in prevalence over time. Data from the MEDALZ (Medication use and Alzheimer's disease) cohort was utilized in the study including all 69,080 community-dwelling persons with new diagnosis of AD during years 2005-2011 in Finland. Four age-, gender- and region of residence-matched persons without AD were identified for each case. Register-based data included prescription drug purchases and comorbidities from Special Reimbursement Register. Annual prevalence of psychotropic drug use one year after diagnosis was determined for each person. Psychotropic drugs were used by 53% of persons with AD compared with 33% of persons without AD during one year after diagnoses. Persons with AD were six times more likely to use antipsychotics and three times more likely to use antidepressants whereas benzodiazepine and related drug (BZDR) use was comparable between persons with and without AD. According to year of AD diagnoses during 2005-2011, antipsychotic use increased from 18% to 20% (p<0.0001) and BZDR use declined from 31% to 26% (p<0.0001) among persons with AD. Widespread utilization of psychotropic drugs was observed among persons with AD. Despite safety warnings of antipsychotic use for BPSD, antipsychotic use increased from 2005 to 2011 among newly diagnosed persons with AD in Finland.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2014.10.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 73

Metadata

Authors
Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A.-M., Tiihonen, J., & Hartikainen, S.
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2014-11
Volume
24
Issue
11
Pages
1729-1737
ISSN
0924-977X (ISSN-L)
OpenAlex
W2049268457
Cited by
73
References
8
FWCI
8.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort. https://app.cochat.ai/papers/10.1016/j.euroneuro.2014.10.004
The paper
Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A.-M., Tiihonen, J., & Hartikainen, S. (2014). High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2014.10.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.